from the promptly evolving field of oncology research, accurate and successful mutation screening is vital for creating focused therapies. The KRAS solutions Platform plays a pivotal position Within this landscape by providing extensive methods for KRAS mutation profiling and Examination. KRAS mutations, found in around ninety five% of RAS-related